Abstract Background Chimeric antigen receptor T-cell therapy (CART) prolongs survival for patients with refractory or relapsed lymphoma. Discrepancies among different response criteria for lymphoma under CART were recently shown. Our objective was to evaluate reasons for discordance among different response criteria and their relation to overall survival. https://www.jmannino.com/mega-save-KangVape-Onee-Stick-Disposable-3000-Puffs-12mL-special-find/